Attached files
| file | filename |
|---|---|
| 8-K - FORM_8K - ViewRay, Inc. | vray-8k_20200312.htm |
| EX-99.2 - EX-99.2 - ViewRay, Inc. | vray-ex992_34.htm |
Exhibit 99.1
ViewRay Reports Fourth Quarter and Full Year 2019 Results
CLEVELAND, March 12, 2020 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2019. A supplemental presentation for today's conference call is included on the Company's website at http://investors.viewray.com/events/event-details/q4-2019-viewray-inc-earnings-conference-call.
Full Year 2019 Highlights:
|
|
• |
Total revenue of $87.8 million compared to 2018 revenue of $81.0 million, which is primarily from 15 revenue units including two system upgrades in each respective year. |
|
|
• |
Received 22 new orders for MRIdian systems, including three upgrades, totaling $118.5 million, compared to 23 new orders totaling $140.7 million in 2018. |
|
|
• |
Total backlog increased to $227.3 million as of December 31, 2019, compared to $212.3 million as of December 31, 2018. |
|
|
• |
Cash and cash equivalents were $226.8 million as of December 31, 2019. The Company received aggregate net proceeds of $138.4 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company, from its December 2019 offering. |
Fourth Quarter 2019 Summary:
|
|
• |
Total revenue was $16.5 million in the quarter, primarily from three revenue units including one system upgrade, compared to $20.7 million, primarily from four revenue units including one system upgrade, for the same period last year. |
“In 2019 we built significant organizational expertise, made progress on our innovation and clinical pipelines, and fortified our balance sheet,” said Scott Drake, President and CEO. “As we look at 2020, our commercial and operational activities are being impacted by the coronavirus and may be further impacted depending upon how the situation unfolds. As we look beyond the coronavirus uncertainty, we are confident in the capabilities we have built and how MRIdian is positioned to improve the paradigm of care."
Financial Results
Total revenue for the three months ended December 31, 2019 was $16.5 million compared to $20.7 million for the same period last year. Total revenue for the full year 2019 was $87.8 million compared to $81.0 million for the full year 2018.
Total cost of revenue for the three months ended December 31, 2019 was $20.4 million compared to $20.1 million for the same period last year. Total cost of revenue was $93.3 million for the full year 2019 compared to $74.4 million for the full year 2018.
Total gross (loss) profit for the three months ended December 31, 2019 was $(3.9) million, compared to $0.6 million for the same period last year. Total gross (loss) profit for the full year 2019 was $(5.5) million compared to $6.6 million for the full year 2018.
Total operating expenses for the three months ended December 31, 2019 were $28.4 million, compared to $22.1 million for the same period last year. Total operating expenses for the full year 2019 were $115.3 million for the full year 2019 compared to $81.7 million for the full year 2018.
Net loss for the three months ended December 31, 2019 was $35.2 million, or $0.31 per share, compared to $16.7 million, or $0.17 per share, for the same period last year. Net loss for the full year 2019 was $120.2 million, or $1.18 per share, compared to $79.1 million, or $0.98 per share, for the full year 2018.
ViewRay had total cash and cash equivalents of $226.8 million at December 31, 2019. From its December 2019 offering, the Company received aggregate net proceeds of $138.4 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.
Financial Guidance
For the full year 2020, ViewRay anticipates total revenue to be in the range of $58 - $95 million, and total cash usage to be in the range of $60 - $80 million. Most notably, commercial and operational activities are being impacted and may be further impacted by the coronavirus. ViewRay has nine planned installations in 2020 in regions that have travel restrictions currently in place.
Conference Call and Webcast
ViewRay will hold a conference call to discuss results on Thursday, March 12, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 6095383. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.com.
After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay's corporate website, www.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until March 19, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 6095383.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay's financial guidance for the full year 2020 and ViewRay's conference calls to discuss its fourth quarter 2019 and year to date results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay's products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its 2019 Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share data)
|
|
|
Three Months Ended December 31, |
|
|
Year Ended December 31, |
|
||||||||||
|
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
|
Gross Orders |
|
$ |
21,210 |
|
|
$ |
48,700 |
|
|
$ |
118,488 |
|
|
$ |
140,717 |
|
|
Backlog |
|
$ |
227,312 |
|
|
$ |
212,311 |
|
|
$ |
227,312 |
|
|
$ |
212,311 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
14,029 |
|
|
$ |
19,389 |
|
|
$ |
79,504 |
|
|
$ |
76,626 |
|
|
Service |
|
|
2,321 |
|
|
|
1,155 |
|
|
|
7,803 |
|
|
|
3,861 |
|
|
Distribution rights |
|
|
119 |
|
|
|
119 |
|
|
|
475 |
|
|
|
475 |
|
|
Total revenue |
|
|
16,469 |
|
|
|
20,663 |
|
|
|
87,782 |
|
|
|
80,962 |
|
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
|
17,078 |
|
|
|
16,958 |
|
|
|
80,446 |
|
|
|
66,522 |
|
|
Service |
|
|
3,325 |
|
|
|
3,105 |
|
|
|
12,814 |
|
|
|
7,837 |
|
|
Total cost of revenue |
|
|
20,403 |
|
|
|
20,063 |
|
|
|
93,260 |
|
|
|
74,359 |
|
|
Gross margin |
|
|
(3,934 |
) |
|
|
600 |
|
|
|
(5,478 |
) |
|
|
6,603 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
6,659 |
|
|
|
4,014 |
|
|
|
23,794 |
|
|
|
16,520 |
|
|
Selling and marketing |
|
|
5,961 |
|
|
|
5,038 |
|
|
|
25,806 |
|
|
|
15,062 |
|
|
General and administrative |
|
|
15,829 |
|
|
|
13,043 |
|
|
|
65,717 |
|
|
|
50,113 |
|
|
Total operating expenses |
|
|
28,449 |
|
|
|
22,095 |
|
|
|
115,317 |
|
|
|
81,695 |
|
|
Loss from operations |
|
|
(32,383 |
) |
|
|
(21,495 |
) |
|
|
(120,795 |
) |
|
|
(75,092 |
) |
|
Interest income |
|
|
330 |
|
|
|
2 |
|
|
|
1,721 |
|
|
|
8 |
|
|
Interest expense |
|
|
(1,425 |
) |
|
|
(1,943 |
) |
|
|
(4,327 |
) |
|
|
(7,701 |
) |
|
Other income (expense), net |
|
|
(1,731 |
) |
|
|
6,696 |
|
|
|
3,202 |
|
|
|
6,389 |
|
|
Loss before provision for income taxes |
|
$ |
(35,209 |
) |
|
$ |
(16,740 |
) |
|
$ |
(120,199 |
) |
|
$ |
(76,396 |
) |
|
Provision for income taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Net loss and comprehensive loss |
|
$ |
(35,209 |
) |
|
$ |
(16,740 |
) |
|
$ |
(120,199 |
) |
|
$ |
(76,396 |
) |
|
Amortization of beneficial conversion feature related to Series A convertible preferred stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,728 |
) |
|
Net loss attributable to common stockholders, basic and diluted |
|
$ |
(35,209 |
) |
|
$ |
(16,740 |
) |
|
$ |
(120,199 |
) |
|
$ |
(79,124 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.31 |
) |
|
$ |
(0.17 |
) |
|
$ |
(1.18 |
) |
|
$ |
(0.98 |
) |
|
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted |
|
|
114,585,685 |
|
|
|
95,822,255 |
|
|
|
102,001,954 |
|
|
|
81,123,140 |
|
(Unaudited)
(In thousands, except share and per share data)
|
|
|
December 31, |
|
|||||
|
|
|
2019 |
|
|
2018 |
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
226,783 |
|
|
$ |
167,432 |
|
|
Accounts receivable |
|
|
16,817 |
|
|
|
36,867 |
|
|
Inventory |
|
|
55,031 |
|
|
|
49,462 |
|
|
Deposits on purchased inventory |
|
|
6,457 |
|
|
|
8,142 |
|
|
Deferred cost of revenue |
|
|
3,466 |
|
|
|
9,736 |
|
|
Prepaid expenses and other current assets |
|
|
3,310 |
|
|
|
6,045 |
|
|
Total current assets |
|
|
311,864 |
|
|
|
277,684 |
|
|
Property and equipment, net |
|
|
23,399 |
|
|
|
13,958 |
|
|
Restricted cash |
|
|
1,404 |
|
|
|
1,933 |
|
|
Intangible assets, net |
|
|
55 |
|
|
|
— |
|
|
Right-of-use assets |
|
|
11,720 |
|
|
|
— |
|
|
Other assets |
|
|
1,577 |
|
|
|
1,395 |
|
|
TOTAL ASSETS |
|
$ |
350,019 |
|
|
$ |
294,970 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
13,739 |
|
|
$ |
10,207 |
|
|
Accrued liabilities |
|
|
21,390 |
|
|
|
9,983 |
|
|
Customer deposits |
|
|
9,662 |
|
|
|
19,968 |
|
|
Operating lease liability, current |
|
|
2,264 |
|
|
|
— |
|
|
Current portion of long-term debt |
|
|
1,556 |
|
|
|
— |
|
|
Deferred revenue, current portion |
|
|
10,457 |
|
|
|
13,731 |
|
|
Total current liabilities |
|
|
59,068 |
|
|
|
53,889 |
|
|
Deferred revenue, net of current portion |
|
|
3,553 |
|
|
|
5,744 |
|
|
Long-term debt |
|
|
53,995 |
|
|
|
55,364 |
|
|
Warrant liability |
|
|
5,373 |
|
|
|
11,844 |
|
|
Operating lease liability, noncurrent |
|
|
10,479 |
|
|
|
— |
|
|
Other long-term liabilities |
|
|
1,377 |
|
|
|
820 |
|
|
TOTAL LIABILITIES |
|
|
133,845 |
|
|
|
127,661 |
|
|
Commitments and contingencies (Note 6) |
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
|
Convertible preferred stock, par value $0.01 per share; 10,000,000 shares authorized at December 31, 2019 and 2018; no shares issued and outstanding at December 31, 2019 and 2018 |
|
|
— |
|
|
|
— |
|
|
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at December 31, 2019 and 2018; 147,191,695 and 96,332,023 shares issued and outstanding at December 31, 2019 and 2018 |
|
|
1,462 |
|
|
|
952 |
|
|
Additional paid-in capital |
|
|
733,888 |
|
|
|
565,334 |
|
|
Accumulated deficit |
|
|
(519,176 |
) |
|
|
(398,977 |
) |
|
TOTAL STOCKHOLDERS’ EQUITY |
|
|
216,174 |
|
|
|
167,309 |
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
350,019 |
|
|
$ |
294,970 |
|
Investor Relations:
Michaella Gallina
Vice President, Chief of Staff, Head of Investor Relations and Communications
ViewRay, Inc.
1-844-MRIdian (674-3426)
Email: investors@viewray.com
Media Enquiries:
Karen Hackstaff
Vice President, Strategy and Brand
ViewRay, Inc.
Phone: +1 408-242-2994
Email: media@viewray.com